Novel Antibody Therapeutics Congress

When

2019年10月10-11日
Registration from 8am

Where

英國,倫敦
London Heathrow Marriott Hotel

Novel Antibody Therapeutics Congress
-新抗體醫藥學會-
日期:2019年10月10-11日
地點:英國,倫敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Novel Antibody Therapeutics Congress

推動抗體與蛋白質醫生藥物進化的研究方面、技術方面、事業方面之最新趨勢

這次學會將安排有以配合癌症治療的抗體醫藥最新發展為焦點的單元,探討雙特異性抗體技術的最新發展,以及探索新抗體和抗體模擬形式的潛力。此外也有以查核點抑制劑為焦點的單元,介紹針對治療用的PD1,PD-L1和CTLA4的進展,以及新生物標記物的發現和標靶化的研究。

“I liked the fact that the conference was really focused ... allowing to learn and discuss specific subjects with experts in the field”

“Excellent opportunity to discuss topics in detail and to network”.

“The research sessions were very good and of high quality”

這個學會是以癌症免疫療法相關研究及技術為主題的一系列活動之一。報名參加這個學會,您除了可以聽取這五個學會中將進行的100多場演講之外,更可拓展您橫跨各專門領域的人脈,吸收到嶄新的知識。

您可參加同時舉辦的這系列所有學會

 

2019年10月10日(四) – 治療癌症所用的抗體


Keynote Address: Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells
RENE HOET, CSO, Imcheck Therapeutics
ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T-cells in-vitro and in-vivo and is planned to enter phase I studies early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.

Keynote Address: Cancer Bispecific Biologics: Current Status and Learnings From Successes and Failures
RAKESH DIXIT, VP, Research & Development and Global Head Biologics Safety, MedImmune
• Overview of landscape of bispecifics targeting cancers
• Preclinical and clinical landscape of bispecifics in oncology
• Five rights of bispecifics: A case study of unique immune checkpoints targeting bispecific
• Learnings from success and failures of bispecifics.


Morning Refreshments / Poster Presentations


Triple Negative Breast Cancer targeted therapy with anti-Folate Receptor alpha antibodies
SOPHIA KARAGIANNIS, Reader in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London
Employing a multi-omics approach we show that the folate carrier Folate Receptor alpha (FRα) is upregulated in triple negative breast carcinomas and that expression of molecules involved in the folate metabolism are dysregulated. FRα is expressed in post-neoadjuvant chemotherapy residual disease, and participates in cancer cell signaling and cancer cell growth. We demonstrate that FRα and the folate cascade could be targeted with specific inhibitors. Furthermore, FRα may present a target for antibody immunotherapy that primes an Fc-mediated anti-tumor immune response, and an antibody-drug conjugate approach that can deliver a pathway inhibitor to FRα-expressing cells. These findings may point to a new treatment avenue for patients with triple negative breast cancer.

Targeted Thorium Conjugates: Novel first in class targeted alpha therapy
JENNY KARLSSON, Head of TCR Biochemistry, Bayer
• Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer.
• TAT has become an established modality in the treatment of metastatic castration-resistant prostate cancer
following the approval of radium-223 dichloride.
• TATs are highly cytotoxic due to the high linear energy transfer of the alpha-particle emitting radionuclide which induces complex DNA double-strand breaks in the targeted tumor cell.
• TTCs consist of a targeting moiety, a chelator covalently linked via an amide bond to the antibody and thorium-227 complexed to the chelator with high affinity.
• Important advantages of TTCs are the lack of known resistance mechanisms to alpha-particle emission and their ability to also kill non-dividing cells.
• Preclinical in vitro and in vivo data will be presented.


Lunch


PANEL DISCUSSION:

Next Generation Antibodies: beyond bispecifics
Speakers include: SYD JOHNSON & RAKESH DIXIT

Bi-specific T-cell Engagers (BiTE®) in Hematological Malignancies
FRANCESCO GALIMI, Global Product General Manager, Early Development, Amgen
The bispecific T-cell engager (BiTE®) blinatumomab (Blincyto®) has recently been approved for Philadelphia
chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It consists of two single chain variable fragments (scFvs) specific for CD19 present on the B-cell lineage, and CD3 expressed on almost all T cells. Based on the potent anti-tumor activity of Blincyto® in B-cell malignancies, BiTE® antibody constructs directed against other target antigens are being tested in a number of malignancies, in particular acute myeloid leukemia and multiple myeloma. We will review the ongoing activities in this field.

Presentation


Afternoon Refreshments / Poster Presentations


POLR2A as a putative predictive biomarker for treatment with Amanitin-based ADCs
CHRISTIAN BREUNIG, Group Leader Biomarker & Cell Biology, Heidelberg Pharma
Heidelberg Pharma develops Antibody Targeted Amanitin Conjugates (ATACs), a new class of Antibody-Drug Conjugates with the cyclic peptide amanitin as the toxic payload. Amanitin blocks the cellular transcription process by specifically binding to the eukaryotic RNA polymerase II. POLR2A, the largest subunit in the human RNA polymerase II complex, is located on chromosome 17p13.1 and in close proximity to TP53. A chromosome 17p deletion is present in any cancer patients correlating with poor survival. Furthermore, we observed that a deletion of POLR2A significantly enhanced treatment efficacy of ATACs in different in vivo models. Based on these observations, Heidelberg Pharma proposes POLR2A as a putative biomarker to identify patients that would benefit the most from treatment with ATACs

Antibody libraries based on an autonomous human variable domain
JOHAN NILVEBRANT, Researcher, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH
Antibodies are tremendously useful for biotechnological applications, diagnostics and therapy. However, their complex architecture has spurred interest in smaller derivatives that can retain the targeting specificity and be more easily produced. We have constructed highly diverse (>1010) libraries based on an autonomous human variable heavy (VH) domain and used these libraries to select specific binders to the human Eph receptor family. Our aim is to use these binders to develop novel tools for specific investigation of blocking or activation of specific Eph receptor homo or heterodimers. Moreover, structural evaluations of first and second-generation binders to EphA1, which have been identified after stress selections on phage, illustrate how VH domains can be stabilized via tailored CDR mutagenesis.


Networking Drinks Reception


2019年10月11日(五) - 癌症免疫療法的格式

Keynote Address: Developing novel checkpoint inhibitors
JUSTIN SCHEER (Reserved), Director, Antibody Engineering, Boehringer-Ingelheim

BiCKI: a novel Bispecific checkpoint inhibitor platform
NICOLAS POIRIER, CSO, OSE Immunotherapeutics
• A proprietary transformative technology restating the current anti-PD-(L)1 standard of care.
• An engineered anti-PD-1 bispecific platform to extend the spectrum of patients responding to immunotherapies.
• BiCKI is the 2nd generation of PD-x inhibitors to increase the efficacy in hard to treat tumor types by addressing
untapped immune evasion mechanisms.
• OSE’s armed anti-PD-1 bispecifics are paving the way to reinstate sustained adaptive and innate immune responses.


Morning Refreshments / Poster Presentations


Engaging multiple cell populations within immune system with a single mAb: designing Swiss Army knives to fight cancer
ROMAN IVANOV, Vice-President, R&D, BIOCAD
• PDL1/CD47 mAb: restoring Teff response and phagocytosis
• PD1/GITR mAb: shifting the Teff/Treg cell balance
• IL15/PD1 mAb: potentiating Teff and NK responses
• Overcoming stability and manufacturability issues
• Cell-based assays for IO bispecifics
• Selection of in vivo models for IO bispecifics

Advancing t cell engaging antibodies for immuno-oncology
JOHN DESJARLAIS (Reserved), Senior Vice President, Research and Chief Scientific Officer, Xencor


Lunch


Novel antibodies beyond PD-1 therapy for cancer immunotherapy
SONIA QUARATINO, Chief Medical Officer, Kymab

An engineered IgG1-IgM tp fusion for enhanced CDC activity
SHIRLEY PETERS, Principal Scientist, UCB
• IgG1-IgM tp fusion promote IgG1 hexamerisation
• Engineering tp fusion leads to on-target hexamerisation.
• On-target hexamerisation results in enhanced C1q recruitment which translates to enhanced CDC activity

Novel multi-drug immuno-oncology and targeted thearpy combinations lead to synergy in preclinical models of B-cell malignancies
EMMANUEL NORMANT, VP Preclinical Sciences, TG Therapeutics New York
• Drug combinations are critical for efficacy in oncology. TG Therapeutics is building a “combinable” pipeline in order to increase the depth of response, decrease the instances of resistance, and tackle financial toxicity.
• The presentation focuses on datasets from in vitro and in vivo preclinical models that demonstrates synergy. The drugs used are the anti-CD20 antibody ublituximab, the PI3K inhibitor umbralisib, and the novel CD47-CD19 bispecific antibody TG-1801.
• We show here that targeting the innate CD47 checkpoint increases the efficacy of antibody-dependent cellular toxicity (ADCC) and phagocytosis (ADCP) driven by the anti-CD20 antibody ublituximab.
• The anti-tumor activity of the ublituximab and umbralisib “U2” combination is also enhanced with the anti-CD47 bispecific antibody, TG-1801, warranting clinical trial evaluating this triple-therapy.

Engineering a novel check point blockade
STEFAN GLUCK (Reserved), VP GMA, Celgene


Chair’s Closing Remarks / Conference Close


* 活動內容有可能不事先告知作更動及調整。

 

議程

由於這個學會針對的是參與研究配合癌症治療的抗體醫藥最新領域人士,所以將吸引350以上該領域的專家。探討雙特異性抗體技術的最新發展,以及探索新抗體和抗體模擬形式的潛力。此外也有以查核點抑制劑為焦點的單元,介紹針對治療用的PD1,PD-L1和CTLA4的進展,以及新生物標記物的發現和標靶化的研究。

Download the Agenda (PDF)

演講者

贊助商

所有贊助商名單

地點

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海報發表

學會的贊助商

募集贊助商

成為這個學會的贊助商或參展商,您可在融洽的氣氛中,一面和專家們交流彼此的意見,同時也有機會和各種組織代表進行官方或非官方會談,以建立彼此的合作關係。

此外我們更準備了各種贊助商配套方案,您可考量自身的預算及業務需求,選擇能讓您獲得最大投資收益的方案。

如果您有除此之外,成為贊助商來開展您宣傳活動的其他建議,也歡迎您隨時與我們連絡,我們將配合您的需求提供各種提案。

可事前預約的二十分鐘一對一個別會談

在主要會議議程的分組會議期間將舉行一系列事先預約的二十分鐘個別會談,選擇您想要會見的代表。在會議期間Global Engage的團隊將隨時待命,確保您的所有會議按時舉行。

主要會議前後的研討會

在主要會議前後,將舉辦為了對特定主題有興趣的與會者所辦的全天或半天研討會。Global Engage將協助您在研討會上進行宣傳活動,並確保夠多人出席。

學會開幕前的行銷和品牌宣傳

您也可利用Global Engage的資料庫來進行行銷,更可揭示海報,成為休息和午餐會、招待會、海報單元的贊助商來提升您的品牌知名度。此外我們也另外提供可在發給與會者的掛繩,和學會資料袋上印刷標誌以提升品牌知名度的選項。

參展

會期中,您可在會場內所設的專用區向所有的與會者發表您的技術及產品。展會區同時也是休息及午餐會,第一天傍晚舉行的招待會的會場。

演講

演講的形態

  • 30分鐘的演講
  • 以主持人或小組成員身分參加30分鐘專題研討會
  • 在學會的議程中召開1小時的研討會
募集贊助商

詳細內容請洽詢GII聯絡處。

包括簽證等各種海關所需文件,以及展示用品的通關手續皆由展商企業各自負責。

展示相關的安排(企業介紹、公司商標、提供與會者目錄中的展商資訊登錄、展示空間的裝潢、用品訂購、展示用品的擺設搬運、展示空間的文件申請、保險等)請直接與主辦方連繫。

旅遊相關疑問(住宿、機票)、當地翻譯人員、飛行與意外保險等問題,將有另外的專門業者分別提供服務。

Novel Antibody Therapeutics Congress的贊助商相關詳情請洽詢聯絡處。

媒體合作夥伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免費電子郵件通知服務